Bank of America Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price

Key Points

• Bank of America cut its price target on WAVE from $38 to $21 while maintaining a "buy" rating, implying roughly 229.98% upside from the current share price.
• Analyst views are mixed but the consensus is a Moderate Buy with an average price target of $31.38, with individual targets ranging from $13 to $41 across firms.
• Shares traded around $6.36 after a quarterly EPS miss (‑$0.30) despite a revenue beat, insiders have recently sold stock, and the name saw sharp moves following mixed Phase 1 INLIGHT data and a related securities‑litigation probe.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) had its target price dropped by analysts at Bank of America from $38.00 to $21.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Bank of America's price target would indicate a potential upside of 229.98% from the company's current price.

Several other brokerages have also recently commented on WVE. Mizuho raised their target price on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday. Wells Fargo & Company cut their price target on WAVE Life Sciences from $27.00 to $13.00 and set an "overweight" rating for the company in a research note on Friday. B. Riley Financial increased their price target on WAVE Life Sciences from $19.00 to $37.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. Morgan Stanley set a $28.00 price objective on WAVE Life Sciences in a research note on Monday, December 8th. Finally, Cantor Fitzgerald lifted their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $31.38.

WAVE Life Sciences Stock Up 2.6%

Shares of WAVE Life Sciences stock traded up $0.16 during trading on Friday, reaching $6.36. The company's stock had a trading volume of 3,510,995 shares, compared to its average volume of 4,151,776. The business's 50-day moving average price is $13.08 and its 200-day moving average price is $11.20. WAVE Life Sciences has a 52 week low of $5.02 and a 52 week high of $21.73. The firm has a market cap of $1.20 billion, a PE ratio of -5.18 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.02). The business had revenue of $17.25 million for the quarter, compared to the consensus estimate of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. Equities analysts predict that WAVE Life Sciences will post -1.14 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Chandra Vargeese sold 3,228 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $43,416.60. Following the sale, the insider directly owned 408,246 shares in the company, valued at approximately $5,490,908.70. This trade represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Chris Francis sold 33,194 shares of WAVE Life Sciences stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the sale, the insider directly owned 61,867 shares in the company, valued at $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 61,748 shares of company stock worth $907,809. 23.98% of the stock is currently owned by company insiders.

Institutional Trading of WAVE Life Sciences

A number of hedge funds have recently added to or reduced their stakes in WVE. CWM LLC grew its stake in shares of WAVE Life Sciences by 6,729.0% in the fourth quarter. CWM LLC now owns 2,117 shares of the company's stock worth $36,000 after purchasing an additional 2,086 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in WAVE Life Sciences by 645.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company's stock worth $38,000 after buying an additional 1,942 shares during the period. Bessemer Group Inc. grew its position in shares of WAVE Life Sciences by 1,156.3% in the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company's stock valued at $72,000 after buying an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of WAVE Life Sciences by 1,441.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock valued at $73,000 after buying an additional 9,284 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in shares of WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company's stock valued at $74,000 after buying an additional 1,802 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Positive Phase 1 INLIGHT data showed statistically significant, clinically meaningful reductions in visceral fat (≈14% placebo‑adjusted), improvements in total fat and lean mass, and reductions in waist circumference and body composition metrics — supporting biological activity and safety. GlobeNewswire release
• Positive Sentiment: Some analysts remain bullish: Mizuho raised its target (to $27) and gave an "outperform" rating, and Truist upgraded to "strong‑buy" — signals that certain firms see longer‑term upside after the sell‑off. Mizuho note (Benzinga)
• Neutral Sentiment: Wells Fargo cut its price target substantially from $27 to $13 but retained an "overweight" rating — a mixed message that lowers near‑term valuation expectations while keeping a constructive stance on the story. Benzinga report
• Negative Sentiment: Market reaction: Investors focused on the minimal placebo‑adjusted weight loss (~0.9% at six months) and a lack of clear dose benefit at the higher dose, prompting sharp intraday selling and large percentage declines in the stock. This immediate liquidity event is the main driver of the price move. Reuters
• Negative Sentiment: Potential legal risk: a securities‑litigation firm (Johnson Fistel) announced an investigation into investor losses, which can add regulatory and legal overhang. GlobeNewswire PR

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.